MERIDIAN DIAGNOSTICS INC
10-K, EX-99, 2000-12-22
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: MERIDIAN DIAGNOSTICS INC, 10-K, EX-27, 2000-12-22
Next: FIRST CAPITAL INSTITUTIONAL REAL ESTATE LTD 4, 8-K, 2000-12-22



<PAGE>   1



                                                                      EXHIBIT 99

                      FORWARD LOOKING STATEMENTS STATEMENT

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from
civil litigation for forward looking statements accompanied by meaningful
cautionary statements. These statements identify important factors that could
cause actual results to differ materially from those that might be projected.
Meridian's continued growth depends, in part, on its ability to introduce into
the marketplace enhancements of existing products or new products that
incorporate technological advances, meet customer requirements and respond to
products developed by Meridian's competition. While Meridian has introduced
approximately 35 internally-developed products since 1991, there can be no
assurance that it will be successful in the future in introducing such products
on a timely basis. Ongoing consolidations of reference laboratories and
formation of multi-hospital alliances may cause adverse changes to pricing and
distribution. On-going efforts in meeting existing and new requirements of the
Food and Drug Administration could adversely affect the sales and costs of
development of Meridian's products. One of Meridian's main growth strategies is
acquisition of companies and product lines. There can be no assurance that
additional acquisitions will be consummated or that, if consummated, will be
successful and the acquired businesses successfully integrated into Meridian's
operations.


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission